SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharmaceutical Industries board approves buyback of equity shares

24 Jun 2016 Evaluate

Sun Pharmaceutical Industries has informed that the Board of Directors of the Company at its meeting held on June 23, 2016, has approved the buyback by the Company of its fully paid up Equity Shares of face value of Re 1 each (‘Equity Shares’) not exceeding 7,500,000 Equity Shares (representing up to 0.31% of the total paid-up Equity Share capital of the Company) at a price of Rs 900 per Equity Share payable in cash for an aggregate amount of up to Rs 6,750,000,000 excluding transaction costs viz. brokerage, securities transaction tax, service tax, stamp duty, etc., which is approximately 3.79% of the fully paid-up Equity Share capital and free reserves (including securities premium account) as per the latest audited standalone balance sheet of the Company for the financial year ended March 31, 2016 on a proportionate basis through the ‘Tender Offer’ route using stock exchange mechanism as prescribed under SEBI (Buy Back of Securities) Regulations, 1998 (the ‘Buyback Regulations’) and the Companies Act, 2013 (the ‘Act’) and rules made there under from the Equity shareholders of the Company who hold Equity Shares as on the record date (‘Buyback’). The Promoter, members of the Promoter Group and Persons in Control of the Company have indicated their intention to participate in the proposed Buyback in such a manner that their aggregate shareholding percentage in the Company will not fall below their current aggregate percentage shareholding. The public announcement setting out the process, timelines and other requisite details will be released in due course in accordance with the Buyback Regulations.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma. Inds. Share Price

1904.65 33.10 (1.77%)
03-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: